Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Given Consensus Recommendation of “Moderate Buy” by Analysts

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) has earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $54.50.

FTH has been the subject of several research analyst reports. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price objective for the company. Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. BTIG Research restated a “buy” rating and set a $55.00 target price on shares of Sensei Biotherapeutics in a research report on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th.

Sensei Biotherapeutics Stock Performance

Shares of Sensei Biotherapeutics stock opened at $25.94 on Friday. The company has a market cap of $34.76 million, a P/E ratio of -0.18 and a beta of -0.26. Sensei Biotherapeutics has a twelve month low of $6.32 and a twelve month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. On average, research analysts anticipate that Sensei Biotherapeutics will post -16.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the transaction, the insider directly owned 130,142 shares in the company, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $19.76 per share, with a total value of $55,446.56. Following the acquisition, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This trade represents a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in FTH. Renaissance Technologies LLC increased its holdings in Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after acquiring an additional 1,100 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics in the first quarter worth $4,188,000. Finally, Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics in the first quarter worth $22,758,000. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.